Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
MRK sits 63% above its 52-week low of $73.31.
Summary
Merck announced it is actively pursuing bolt-on acquisitions, both large and small, to strengthen its drug pipeline. This strategic move is critical as the company prepares for the 2028 patent expiration of its top-selling drug, Keytruda, which generated approximately $31.7 billion in sales in 2025. This follows the company's recent 10-K filing which warned of material future revenue declines for Keytruda and a DEF 14A outlining a strong strategic vision for future growth. The acquisition strategy aims to mitigate the anticipated revenue impact and maintain growth, demonstrating a proactive approach to a significant known challenge. Traders will be watching for specific deal announcements and the financial implications of these acquisitions.
At the time of this announcement, MRK was trading at $119.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $297.1B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.